vs
Side-by-side financial comparison of CUMBERLAND PHARMACEUTICALS INC (CPIX) and Paysign, Inc. (PAYS). Click either name above to swap in a different company.
Paysign, Inc. is the larger business by last-quarter revenue ($22.8M vs $13.7M, roughly 1.7× CUMBERLAND PHARMACEUTICALS INC). Paysign, Inc. runs the higher net margin — 6.0% vs -10.3%, a 16.3% gap on every dollar of revenue. On growth, Paysign, Inc. posted the faster year-over-year revenue change (45.8% vs 31.1%). Paysign, Inc. produced more free cash flow last quarter ($47.5M vs $3.0K). Over the past eight quarters, Paysign, Inc.'s revenue compounded faster (31.3% CAGR vs 26.9%).
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company that develops, manufactures and commercializes branded prescription medicines. Its core product portfolio covers acute care, gastroenterology, pain management and rare disease treatment, with its primary operating market being the United States, serving healthcare providers and patients in relevant care segments.
Paysign, Inc. is a specialized payment solutions provider that designs and delivers customized prepaid card programs, end-to-end payment processing services, and digital disbursement tools. Its core served segments include healthcare, corporate incentives, and general consumer markets, with primary operations and client bases across North America.
CPIX vs PAYS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.7M | $22.8M |
| Net Profit | $-1.4M | $1.4M |
| Gross Margin | 83.6% | 57.7% |
| Operating Margin | -10.0% | 8.1% |
| Net Margin | -10.3% | 6.0% |
| Revenue YoY | 31.1% | 45.8% |
| Net Profit YoY | 25.8% | -0.7% |
| EPS (diluted) | $-0.09 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.7M | $22.8M | ||
| Q3 25 | $8.3M | $21.6M | ||
| Q2 25 | $10.8M | $19.1M | ||
| Q1 25 | $11.7M | $18.6M | ||
| Q4 24 | $10.4M | $15.6M | ||
| Q3 24 | $9.1M | $15.3M | ||
| Q2 24 | $9.8M | $14.3M | ||
| Q1 24 | $8.5M | $13.2M |
| Q4 25 | $-1.4M | $1.4M | ||
| Q3 25 | $-1.9M | $2.2M | ||
| Q2 25 | $-740.7K | $1.4M | ||
| Q1 25 | $1.3M | $2.6M | ||
| Q4 24 | $-1.9M | $1.4M | ||
| Q3 24 | $-1.5M | $1.4M | ||
| Q2 24 | $-1.1M | $697.1K | ||
| Q1 24 | $-1.9M | $309.1K |
| Q4 25 | 83.6% | 57.7% | ||
| Q3 25 | 88.1% | 56.3% | ||
| Q2 25 | 81.4% | 61.6% | ||
| Q1 25 | 87.8% | 62.9% | ||
| Q4 24 | 81.1% | 58.9% | ||
| Q3 24 | 85.4% | 55.5% | ||
| Q2 24 | 82.6% | 52.9% | ||
| Q1 24 | 81.5% | 52.6% |
| Q4 25 | -10.0% | 8.1% | ||
| Q3 25 | -23.7% | 7.3% | ||
| Q2 25 | -6.9% | 7.5% | ||
| Q1 25 | 11.0% | 13.4% | ||
| Q4 24 | -17.7% | 3.0% | ||
| Q3 24 | -18.6% | 4.5% | ||
| Q2 24 | -10.4% | 0.9% | ||
| Q1 24 | -22.0% | -2.0% |
| Q4 25 | -10.3% | 6.0% | ||
| Q3 25 | -23.4% | 10.3% | ||
| Q2 25 | -6.8% | 7.3% | ||
| Q1 25 | 10.7% | 13.9% | ||
| Q4 24 | -18.2% | 8.8% | ||
| Q3 24 | -17.0% | 9.4% | ||
| Q2 24 | -11.0% | 4.9% | ||
| Q1 24 | -22.9% | 2.3% |
| Q4 25 | $-0.09 | $0.02 | ||
| Q3 25 | $-0.13 | $0.04 | ||
| Q2 25 | $-0.05 | $0.02 | ||
| Q1 25 | $0.08 | $0.05 | ||
| Q4 24 | $-0.13 | $0.02 | ||
| Q3 24 | $-0.11 | $0.03 | ||
| Q2 24 | $-0.08 | $0.01 | ||
| Q1 24 | $-0.14 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.4M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $24.9M | $48.5M |
| Total Assets | $76.8M | $276.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.4M | — | ||
| Q3 25 | $15.2M | — | ||
| Q2 25 | $16.1M | — | ||
| Q1 25 | $15.1M | — | ||
| Q4 24 | $18.0M | — | ||
| Q3 24 | $17.5M | — | ||
| Q2 24 | $17.3M | — | ||
| Q1 24 | $18.5M | — |
| Q4 25 | $24.9M | $48.5M | ||
| Q3 25 | $26.1M | $45.8M | ||
| Q2 25 | $28.0M | $42.2M | ||
| Q1 25 | $28.7M | $39.3M | ||
| Q4 24 | $22.9M | $30.4M | ||
| Q3 24 | $24.8M | $28.5M | ||
| Q2 24 | $26.3M | $26.9M | ||
| Q1 24 | $27.5M | $25.5M |
| Q4 25 | $76.8M | $276.3M | ||
| Q3 25 | $65.9M | $209.5M | ||
| Q2 25 | $67.9M | $193.9M | ||
| Q1 25 | $69.9M | $205.1M | ||
| Q4 24 | $75.6M | $179.0M | ||
| Q3 24 | $76.7M | $167.0M | ||
| Q2 24 | $78.5M | $182.3M | ||
| Q1 24 | $81.5M | $173.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.0K | $48.1M |
| Free Cash FlowOCF − Capex | $3.0K | $47.5M |
| FCF MarginFCF / Revenue | 0.0% | 208.7% |
| Capex IntensityCapex / Revenue | 0.0% | 2.6% |
| Cash ConversionOCF / Net Profit | — | 35.29× |
| TTM Free Cash FlowTrailing 4 quarters | $4.8M | $51.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0K | $48.1M | ||
| Q3 25 | $187.2K | $6.8M | ||
| Q2 25 | $843.8K | $3.6M | ||
| Q1 25 | $3.9M | $-6.0M | ||
| Q4 24 | $1.9M | $14.3M | ||
| Q3 24 | $475.5K | $-20.2M | ||
| Q2 24 | $-855.7K | $20.6M | ||
| Q1 24 | $-2.1M | $8.2M |
| Q4 25 | $3.0K | $47.5M | ||
| Q3 25 | $163.4K | $6.3M | ||
| Q2 25 | $817.3K | $3.6M | ||
| Q1 25 | $3.9M | $-6.1M | ||
| Q4 24 | $1.9M | $14.2M | ||
| Q3 24 | $460.1K | $-20.3M | ||
| Q2 24 | $-862.8K | $20.4M | ||
| Q1 24 | $-2.2M | $8.2M |
| Q4 25 | 0.0% | 208.7% | ||
| Q3 25 | 2.0% | 29.2% | ||
| Q2 25 | 7.5% | 18.6% | ||
| Q1 25 | 32.9% | -32.9% | ||
| Q4 24 | 18.2% | 91.0% | ||
| Q3 24 | 5.1% | -133.0% | ||
| Q2 24 | -8.8% | 142.4% | ||
| Q1 24 | -25.6% | 62.1% |
| Q4 25 | 0.0% | 2.6% | ||
| Q3 25 | 0.3% | 2.1% | ||
| Q2 25 | 0.2% | 0.5% | ||
| Q1 25 | 0.4% | 0.4% | ||
| Q4 24 | 0.0% | 0.7% | ||
| Q3 24 | 0.2% | 0.8% | ||
| Q2 24 | 0.1% | 1.0% | ||
| Q1 24 | 0.5% | 0.4% |
| Q4 25 | — | 35.29× | ||
| Q3 25 | — | 3.05× | ||
| Q2 25 | — | 2.62× | ||
| Q1 25 | 3.10× | -2.33× | ||
| Q4 24 | — | 10.43× | ||
| Q3 24 | — | -14.03× | ||
| Q2 24 | — | 29.48× | ||
| Q1 24 | — | 26.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CPIX
Segment breakdown not available.
PAYS
| Plasma Industry | $12.6M | 55% |
| Pharma Industry | $9.6M | 42% |
| Other | $558.4K | 2% |
